Next Article in Journal
A Soxhlet Extract of Gongronema latifolium Retains Moderate Blood Glucose Lowering Effect and Produces Structural Recovery in the Pancreas of STZ-Induced Diabetic Rats
Previous Article in Journal
Evaluation of Electrolytes Imbalance and Dyslipidemia in Diabetic Patients
Article

Chemo-Immunotherapy Using Lentinan for the Treatment of Gastric Cancer with Liver Metastases

1
Department of Medical Oncology, Nagoya Memorial Hospital, 4-305 Hirabari, Tenpaku-ku, Nagoya 468-8520, Japan
2
Department of Clinical Oncology, Nagoya Memorial Hospital, Nagoya 468-8520, Japan
3
School of Nursing and Health, Aichi Prefectural University, Nagoya 463-8502, Japan
*
Author to whom correspondence should be addressed.
Academic Editor: Hung-Yun Lin
Med. Sci. 2016, 4(2), 8; https://doi.org/10.3390/medsci4020008
Received: 1 February 2016 / Revised: 25 March 2016 / Accepted: 28 March 2016 / Published: 7 April 2016
Gastric cancer is the third leading cause of cancer-related mortality worldwide. Systemic chemotherapy is the main treatment option for advanced gastric cancer when the tumor is inoperable. Despite recent advances in chemotherapeutic agents, the prognosis of unresectable or recurrent gastric cancer remains extremely poor. In Japan, combination therapy including S-1 and cisplatin is the standard first-line treatment for advanced gastric cancer; however, the five-year survival rate remains very low. Lentinan, the backbone of beta-(1,3)-glucan with beta-(1,6) branches, an active ingredient purified from Shiitake mushrooms, has been approved as a biological response modifier for the treatment of gastric cancer. This agent has been used in combination with oral fluoropyrimidines to improve the overall survival of gastric cancer patients. A retrospective chart review on 138 metastatic gastric cancer patients receiving chemotherapy was performed in Nagoya Memorial Hospital from 1 September 2010 to 31 August 2015. 12 patients with liver metastases were treated by lentinan in combination with S-1-based chemotherapy. The rate of objective response was 42% (5/12) and the disease control rate was 83% (10/12) in response to chemo-immunotherapy using lentinan, with a median overall survival of 407 days (95% CI: 207–700 days). View Full-Text
Keywords: lentinan; trastuzumab; gastric cancer; liver metastases; chemo-immunotherapy lentinan; trastuzumab; gastric cancer; liver metastases; chemo-immunotherapy
Show Figures

Figure 1

MDPI and ACS Style

Ina, K.; Furuta, R.; Kataoka, T.; Kayukawa, S.; Ina, H.; Yoneda, M. Chemo-Immunotherapy Using Lentinan for the Treatment of Gastric Cancer with Liver Metastases. Med. Sci. 2016, 4, 8. https://doi.org/10.3390/medsci4020008

AMA Style

Ina K, Furuta R, Kataoka T, Kayukawa S, Ina H, Yoneda M. Chemo-Immunotherapy Using Lentinan for the Treatment of Gastric Cancer with Liver Metastases. Medical Sciences. 2016; 4(2):8. https://doi.org/10.3390/medsci4020008

Chicago/Turabian Style

Ina, Kenji, Ryuichi Furuta, Takae Kataoka, Satoshi Kayukawa, Hiroko Ina, and Masahiko Yoneda. 2016. "Chemo-Immunotherapy Using Lentinan for the Treatment of Gastric Cancer with Liver Metastases" Medical Sciences 4, no. 2: 8. https://doi.org/10.3390/medsci4020008

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop